Leveraging Algorithmic and Machine Learning Technologies for Breast Cancer Management in Sub-Saharan Africa

Frank Nwaogelenya OPIA [1*], Kayode A MATTHEW [2], Temitayo Femi MATTHEW [3]

[1] Accident and Emergency Department, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria

[2] Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States

[3] College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria

* Corresponding Author: **Frank Nwaogelenya OPIA**

Article Info

ISSN (online): 2582-8940
Volume: 03
Issue: 04
October-December 2022
Received: 10-11-2022
Accepted: 12-12-2022
Page No: 107-121

Abstract

Due to delayed diagnosis, few treatment choices, and inadequate healthcare infrastructure, breast cancer continues to be a major worldwide health concern, with some of the greatest fatality rates occurring in Sub-Saharan Africa. By improving the treatment of breast cancer, machine learning (ML) and algorithmic technologies provide a game-changing chance to solve these issues. This study examines the current state of breast cancer in Sub-Saharan Africa, emphasizing the disease's startling prevalence and death rates as well as the structural and systemic obstacles to quality care, such as a lack of diagnostic resources, restricted access to treatment, and socioeconomic considerations. ML has a lot of potential in the medical field, especially in the areas of breast cancer early detection, diagnosis, and therapy planning. Medical image analysis and patient prediction have shown the effectiveness of machine learning models, including supervised, unsupervised, and reinforcement learning methods. However, implementing these technologies in Sub-Saharan Africa requires overcoming several barriers, including poor data availability, limited infrastructure, and a shortage of trained professionals. This paper highlights the importance of partnerships between governments, international organizations, and the tech industry in bridging these gaps. Recommendations include improving healthcare infrastructure, training healthcare workers, and developing region-specific ML models using local datasets to ensure cultural and contextual relevance. Addressing ethical concerns, such as data privacy and equitable access, is also emphasized to ensure the sustainable and inclusive adoption of these technologies. By leveraging ML and algorithmic technologies, Sub-Saharan Africa has the potential to significantly improve breast cancer outcomes, reduce mortality rates, and build a more robust and equitable healthcare system. Continued research, investment, and collaboration will be pivotal in achieving this vision.

DOI: https://doi.org/10.54660/IJMBHR.2022.3.1.48-62

Keywords: Algorithm, Machine Learning, Technologies, Breast Cancer, Management, Sub-Saharan Africa

Introduction

One of the most common and fatal cancers in the world, breast cancer is a significant public health concern (Waljee *et al.*, 2022). The World Health Organization (WHO) estimates that breast cancer accounts for around 25% of all cancer cases worldwide, making it the most frequent disease among women. An projected 2.3 million new instances of breast cancer and over 685,000 fatalities from the illness were reported in 2020 alone (Adeoye *et al.*, 2022). Low- and middle-income countries (LMICs), especially those in Sub-Saharan Africa, have greater death rates from breast cancer, despite high-income nations having higher incidence rates, mostly because of better screening and early diagnosis. This discrepancy is largely attributed to the challenges associated with timely diagnosis, limited access to quality treatment, and a lack of healthcare infrastructure in many parts of the world. Breast cancer develops in the cells of the breast and can spread to other parts of the body if not detected early. Symptoms can include a lump in the breast, changes in breast shape or skin texture, and unusual pain or discharge (Thomford *et al*., 2020). Early detection through screening, such as mammograms, and prompt treatment are key to improving survival rates. However, in many regions, breast cancer is diagnosed at later stages when the disease has already spread, making treatment more complex and less effective. This is particularly true in Sub-Saharan Africa, where the healthcare systems face considerable challenges (Saleh *et al*., 2019). Sub-Saharan Africa is home to a population of over 1.1 billion people, with the majority living in low-resource settings. While the region has made some progress in improving healthcare access and outcomes in recent years, significant gaps remain in terms of infrastructure, healthcare financing, and human resources (MOYO, 2022). Healthcare services, particularly in rural areas, are often inadequate and underfunded, and access to diagnostic tools and modern medical technology is limited. This situation is exacerbated by a shortage of healthcare professionals, including oncologists and radiologists, making it difficult to provide the level of care necessary for early detection and effective treatment of breast cancer. Breast cancer is often diagnosed late in Sub-Saharan Africa, with many patients presenting at advanced stages of the disease when treatment options are less effective (Akuoko, 2020). The lack of organized screening programs, especially for women in rural areas, contributes to late-stage diagnoses. Cultural barriers, such as stigma associated with cancer and limited awareness of the importance of early detection, further compound the issue. Financial constraints also play a significant role, as the costs of diagnostic tests, surgery, chemotherapy, and radiation therapy are prohibitive for many individuals, particularly in countries where out-of-pocket expenses are the primary means of financing healthcare (Ikerionwu *et al*., 2022, Alli and Dada, 2021). The challenges in breast cancer management are not limited to diagnosis and treatment. Follow-up care, which is essential for monitoring patients after surgery or chemotherapy, is often unavailable or poorly coordinated in Sub-Saharan Africa. Additionally, the lack of centralized cancer registries and comprehensive data on cancer trends limits the ability to implement evidence-based policies and allocate resources effectively (Liu *et al*., 2022).

In the face of these challenges, there is growing interest in leveraging technology to improve healthcare delivery in Sub-Saharan Africa. Among the most promising technological advancements are algorithmic and machine learning (ML) technologies, which have the potential to revolutionize breast cancer management in the region (Gupta *et al*., 2021). ML is a subset of artificial intelligence (AI) that enables computers to learn from data and make predictions or decisions without being explicitly programmed. In healthcare, ML has been successfully used for tasks such as disease detection, prognosis prediction, personalized treatment planning, and optimizing healthcare resource allocation (Pareek *et al*., 2022). For breast cancer, ML models can be applied in various aspects of care, starting with early detection. For example, ML algorithms can analyze medical imaging, such as mammograms and ultrasound images, to identify suspicious lesions or tumors that may be indicative of breast cancer. These algorithms can improve the accuracy of diagnosis by reducing human error and providing a second opinion to radiologists (Li *et al*., 2021). In some cases, ML models have demonstrated performance comparable to or even exceeding that of human experts in detecting breast cancer from medical images. The ability to automate and streamline the detection process can help overcome the shortage of radiologists in Sub-Saharan Africa and reduce the time needed for diagnosis (Kimera *et al*., 2020). Beyond imaging, ML can also be used to develop risk prediction models that estimate a person's likelihood of developing breast cancer based on various factors, such as age, family history, genetic predisposition, and lifestyle choices. These models could be particularly useful in countries where there are limited resources for widespread screening, allowing for targeted interventions for individuals at high risk. Machine learning can also play a role in treatment decision-making (Achilonu *et al*., 2022). By analyzing large datasets of patient information, including genetic data, clinical outcomes, and response to treatment, ML models can help personalize treatment plans for individual patients. This could improve outcomes by ensuring that patients receive the most appropriate therapies based on their unique characteristics (Santosh & Gaur, 2022). Furthermore, ML technologies can assist healthcare professionals in predicting disease progression, identifying patients at risk of relapse, and recommending timely follow-up interventions. Despite the potential benefits, the integration of ML technologies in healthcare in Sub-Saharan Africa presents a set of challenges (Boppart & Richards-Kortum, 2014). There is a need for high-quality data to train ML models, which may be difficult to obtain in regions where healthcare records are often paper-based or incomplete. Furthermore, the deployment of ML technologies requires access to appropriate infrastructure, such as reliable internet connectivity, electricity, and hardware capable of supporting complex algorithms (Haney *et al*., 2017). To properly use these technologies, healthcare professionals also require training, which necessitates funding for education and capacity building. However, ML technologies have great potential for enhancing breast cancer management in Sub-Saharan Africa with the correct investments in data collecting, education, and infrastructure. ML has the potential to lessen the burden of breast cancer in the area and increase patient survival rates by cutting down on diagnosis delays, streamlining treatment plans, and improving follow-up care (Crouch *et al*., 2019). In summary, breast cancer is still a major worldwide health concern, and it has an especially bad effect in Sub-Saharan Africa, where healthcare systems are beset by difficulties. Algorithmic and machine learning technologies offer a promising solution to address many of these challenges, from early detection to personalized treatment planning (PAI *et al*., 2016). While there are barriers to their implementation, the potential of these technologies to transform breast cancer management in Sub-Saharan Africa cannot be ignored. Continued investment in these technologies, along with improvements in infrastructure and education, will be essential to realizing their full potential (Elkefi & Layeb, 2022).

2. Methodology

The methodology for leveraging algorithmic and machine learning technologies for breast cancer management in Sub-Saharan Africa involves systematic steps tailored to the region's unique healthcare challenges. The first step focuses on identifying and collecting data from existing sources such as free-text pathology reports, imaging data, and cancer registries while collaborating with local healthcare institutions to acquire new data, including imaging and clinical records. This data encompasses demographics, tumor molecular subtypes, treatment histories, and other relevant features. Ethical considerations are paramount, ensuring patient confidentiality and adherence to local regulations.

Collected data undergoes rigorous preprocessing to address missing information, normalize imaging formats, and standardize free-text reports. Expert annotation by pathologists ensures accurate labeling of biomarkers and clinical parameters. Techniques like oversampling or synthetic data generation address class imbalances in datasets, improving the robustness of the subsequent analyses.

Machine learning models are then developed to analyze the preprocessed data. Supervised learning algorithms are employed for diagnosis and risk stratification, while unsupervised methods identify emerging patterns and insights. Feature selection prioritizes predictive biomarkers, imaging characteristics, and molecular profiles. The models are trained and validated using local datasets, incorporating cross-validation and hyperparameter optimization to enhance sensitivity, specificity, and overall accuracy.

The implementation phase integrates these models into healthcare workflows through user-friendly interfaces designed for radiologists and clinicians. Mobile health platforms are leveraged to ensure accessibility and utility in resource-constrained settings. Pilot studies in hospitals across Sub-Saharan Africa validate the clinical feasibility and effectiveness of the models. Additionally, healthcare workers are trained on the tools to enable early detection and personalized treatment planning.

Evaluation of the implemented systems involves assessing their performance based on metrics like accuracy, sensitivity, and specificity. Impact analysis examines improvements in survival rates and reductions in late-stage diagnoses. Feedback loops from healthcare providers and outcomes are used to refine and improve the models iteratively.

Scalability and sustainability are addressed by advocating for policy integration and national adoption of these algorithmic tools. Low-cost computational platforms are utilized to optimize resources and expand access to the tools. These efforts ensure the long-term applicability and impact of machine learning technologies in managing breast cancer within the region. Figure 1 shows the visual representation of the methodology.



Fig 1: flowchart of the methodology used

2.1 Current Status of Breast Cancer Management in Sub-Saharan Africa

Given its high prevalence and detrimental effects on mortality, breast cancer represents a significant public health concern in Sub-Saharan Africa. The incidence of breast cancer has been rising rapidly over the past few decades, despite the fact that rates are typically lower in the area than in high-income nations (Mulukuntla & Gaddam, 2017). This is a result of both better diagnosis and reporting as well as shifting lifestyles, urbanization, and the adoption of Western eating practices. Breast cancer is the most prevalent disease among women in Sub-Saharan Africa, according to the International Agency for Research on Cancer (IARC), and it is responsible for a significant amount of the region's cancer-related fatalities. In 2020, it was estimated that there were over 165,000 new cases of breast cancer in Sub-Saharan Africa, with more than 75,000 deaths resulting from the disease (Kiyasseh *et al.*, 2020). These figures represent a significant public health burden. The incidence of breast cancer varies across different countries within Sub-Saharan Africa, with higher rates in countries like South Africa, Kenya, and Nigeria, but it is important to note that the true extent of the disease is likely underreported due to a lack of cancer registries and incomplete data (National Academies of Sciences, Engineering, and Medicine. 2018).



Fig 2: Schematic of Africa countries with higher rate of breast cancer incidence

Additionally, the population in Sub-Saharan Africa is relatively young, and breast cancer in this context is often diagnosed in younger women, which contributes to the higher mortality rate compared to high-income countries (Pan *et al*., 2022). The mortality rate in Sub-Saharan Africa is disproportionately high compared to global averages, with women in the region having a significantly lower chance of surviving breast cancer. A key factor behind this disparity is the late-stage presentation of the disease. In many cases, women are diagnosed when the cancer has already spread beyond the breast, making treatment more complex and less effective (Chui *et al*., 2018). The lack of early detection programs and access to screening facilities further exacerbates this situation (Ramanujam & Crouch, 2019). In Sub-Saharan Africa, only a small proportion of women have access to mammography, which is the gold standard for early detection of breast cancer. The five-year survival rate for breast cancer patients in Sub-Saharan Africa is significantly lower than in developed countries (Kimera *et al*., 2020). While the survival rate in high-income countries can exceed 80% due to early detection and advanced treatment options, in Sub-Saharan Africa, this figure is often below 50%. In some countries, it may be as low as 40% or less. This stark difference underscores the need for urgent action to address the underlying factors contributing to late-stage diagnosis and poor treatment outcomes (Ngwa *et al*., 2020).

The healthcare infrastructure in Sub-Saharan Africa is often inadequate to support the management of breast cancer, and this is one of the primary reasons for the region's high mortality rates (Christin-Maitre, 2013). The challenges facing the healthcare systems include insufficient funding, limited medical equipment, and a shortage of skilled healthcare professionals. In many countries, cancer care is concentrated in a few urban centers, leaving rural populations without adequate access to diagnostic and treatment services (Grindlay *et al*., 2013). The result is a significant healthcare access gap between urban and rural populations, with rural women often having to travel long distances to access care, which may delay diagnosis and treatment. In terms of diagnosis, one of the primary limitations is the lack of access to imaging technologies such as mammography and ultrasound. These diagnostic tools are essential for the early detection of breast cancer, but many healthcare facilities in Sub-Saharan Africa do not have the necessary equipment or trained personnel to operate it (Kennedy *et al*., 2019). As a result, breast cancer is often diagnosed at later stages, when the disease is more difficult to treat. For example, in countries like Uganda and Tanzania, mammography services are available in only a few cities, and the limited number of radiologists means that access to screenings is restricted. In addition to diagnostic challenges, the treatment options available in Sub-Saharan Africa are often limited and vary widely across the region (Shah *et al*., 2018). Chemotherapy and surgery are the primary treatment modalities available, with radiation therapy often being unavailable or unaffordable for many patients. The cost of chemotherapy drugs, surgical procedures, and hospital stays can be prohibitive for many individuals, especially in countries where healthcare systems are underfunded, and out-of-pocket expenses are common (Upadhya *et al*., 2017). As a result, many women are unable to complete their treatment regimens or delay treatment until the disease has progressed. Another significant challenge is the lack of multidisciplinary cancer care teams. In high-income countries, breast cancer treatment typically involves a combination of surgery, chemotherapy, radiation therapy, and targeted therapies, all coordinated by a team of oncologists, surgeons, radiologists, and other healthcare professionals. In Sub-Saharan Africa, however, the shortage of specialized healthcare professionals means that many patients are treated in isolation, without the benefit of a comprehensive care plan (Helland, 2019). This not only impacts the quality of treatment but also contributes to the mental and emotional toll on patients, as they often have to navigate the complex healthcare system with limited support. Follow-up care, which is crucial for detecting relapse or managing long-term side effects of treatment, is another area where the healthcare system in Sub-Saharan Africa falls short. In many countries, patients are not regularly monitored after completing their treatment, leading to missed opportunities for early intervention in the case of recurrence or metastasis. This lack of comprehensive follow-up care further exacerbates the high mortality rate from breast cancer in the region (Tenti *et al*., 2020).

Cultural factors play a significant role in shaping how breast cancer is perceived and managed in Sub-Saharan Africa. In many societies, there is a stigma associated with cancer, and patients may be reluctant to seek medical help due to fear of diagnosis, cultural beliefs, or the perception that cancer is a death sentence (Elebro, 2017). In some communities, there is a lack of awareness about the importance of early detection, and many women are unaware of the signs and symptoms of breast cancer. This results in delayed presentation to healthcare providers, which contributes to the high proportion of late-stage diagnoses. In addition to stigma, gender dynamics and social norms often complicate access to breast cancer care for women (Shukla *et al*., 2017). In many parts of Sub-Saharan Africa, women have limited control over financial and healthcare decisions, and their healthcare needs may be deprioritized in favor of other family responsibilities. This can lead to delays in seeking medical attention, as women may not have the resources or support to pay for diagnostic tests or treatment. Furthermore, some women may face challenges in obtaining consent for medical treatment from male family members, especially in more traditional communities (Yang *et al*., 2013). Economic factors also play a critical role in determining access to breast cancer care. In many Sub-Saharan African countries, the cost of healthcare is high, and cancer treatment is often considered a luxury that is beyond the reach of most people (Renner & Jensen, 2011). Many women are forced to choose between spending money on cancer treatment and meeting other basic needs such as food, housing, and education (Cipriani *et al*., 2020). The lack of universal health coverage in many countries means that out-of-pocket costs can create significant financial barriers to care, leading some women to forgo treatment altogether. Finally, the level of education and awareness about breast cancer varies widely in Sub-Saharan Africa. While some urban areas have robust educational campaigns about cancer, many rural areas lack access to information. The lack of public awareness about breast cancer can lead to misconceptions about the disease and reduce the likelihood of early detection (Ampatzis *et al*., 2020). Furthermore, many women in rural areas have limited education and may not understand the importance of screening or early intervention. Educational campaigns that promote awareness of breast cancer, its symptoms, and the importance of regular screening are crucial in improving early detection rates and reducing mortality. Breast cancer management in Sub-Saharan Africa is hindered by a combination of challenges related to healthcare infrastructure, economic barriers, cultural beliefs, and lack of education (Hampson, 2020). These factors contribute to the high mortality rate and low survival rates observed in the region. Addressing these challenges requires a multifaceted approach, including improving access to diagnostic services, expanding treatment options, and raising awareness about the importance of early detection and prevention (De Leo *et al*., 2016). With the right interventions, it is possible to improve breast cancer outcomes in Sub-Saharan Africa and reduce the disproportionate burden of the disease in the region.

2.2 Algorithmic and Machine Learning Technologies

By offering novel approaches to illness diagnosis, prognosis, and treatment, algorithmic and machine learning (ML) technologies are completely changing the healthcare industry (Harvey *et al*., 2004). The creation of algorithms that can learn from data, see patterns, and make judgments or predictions without explicit programming is known as machine learning, a subset of artificial intelligence (AI). In the healthcare industry, machine learning (ML) approaches have shown promise in analyzing medical data, supporting clinical decision-making, and improving patient outcomes. Medical imaging analysis, illness outcome prediction, treatment plan personalization, hospital operations optimization, and real-time patient health monitoring are just a few of the many healthcare jobs that machine learning (ML) may be used for (Yaghjyan *et al*., 2022). The ability of ML to process vast amounts of data and learn from it enables the development of sophisticated models that can enhance diagnostic accuracy, support clinical decision-making, and improve efficiency in healthcare delivery (Boyd *et al*., 2011). The integration of ML into healthcare systems has the potential to address some of the key challenges faced by the sector, particularly in low-resource settings like Sub-Saharan Africa, where there is often a shortage of skilled healthcare professionals, limited access to diagnostic tools, and a lack of comprehensive health data (Yaghjyan *et al*., 2012). By automating complex tasks, ML can assist healthcare workers in making more accurate and timely diagnoses, reduce the workload on medical professionals, and improve the overall efficiency of healthcare systems.

In medical diagnostics, several types of ML models are used to analyze data and make predictions as shown in figure 3. The most commonly used types of ML in healthcare are supervised learning, unsupervised learning, and reinforcement learning (Tesic *et al*., 2013).



Fig 3: Schematic of Machine Learning used in Medical Diagnostics

Each of these models serves different purposes and has unique applications in the diagnosis, treatment, and management of diseases, including breast cancer (Alli and Dada, 2022). Supervised learning is the most widely used form of machine learning in healthcare. In supervised learning, an algorithm is trained on labeled data, meaning the input data is paired with corresponding output labels. The goal is for the algorithm to learn the mapping between inputs and outputs so that it can predict the correct output for new, unseen data (Kanadys *et al*., 2021). In medical diagnostics, supervised learning is typically used for tasks like classification, regression, and prediction. For example, in breast cancer diagnosis, supervised learning algorithms can be trained on medical imaging data, such as mammograms or histopathology images, where each image is labeled as either benign or malignant (Moore *et al*., 2020). By learning the features of these images, the algorithm can develop the ability to classify new images and detect breast cancer with high accuracy (Ramón *et al*., 2015). Common supervised learning algorithms used in healthcare include decision trees, support vector machines (SVM), and neural networks, particularly deep learning models, which have shown great promise in medical image analysis. Unsupervised learning involves training algorithms on data without labels. The goal is to identify hidden patterns, structures, or relationships within the data. In healthcare, unsupervised learning is often used for clustering, anomaly detection, and dimensionality reduction. For example, in breast cancer management, unsupervised learning can be used to cluster patients into groups based on their medical history, genetic data, or response to treatment (Marchbanks *et al*., 2012). These clusters can help identify subtypes of breast cancer that may require different treatment strategies. Unsupervised learning can also be used to discover novel biomarkers or genetic signatures associated with breast cancer, which can aid in early detection and personalized treatment. Common algorithms used in unsupervised learning include k-means clustering, hierarchical clustering, and principal component analysis (PCA). Reinforcement learning is a type of machine learning in which an agent learns to make decisions by interacting with an environment and receiving feedback in the form of rewards or penalties. In healthcare, reinforcement learning is used in areas where decision-making is sequential and involves long-term outcomes, such as personalized treatment planning, optimization of hospital resources, and robotic surgery (Beaber *et al*., 2014). In the context of breast cancer treatment, reinforcement learning can be used to optimize treatment regimens. For instance, an algorithm can be trained to recommend the best treatment plan for a patient based on factors such as the patient's cancer stage, genetic profile, and overall health. The algorithm learns through trial and error, improving its recommendations over time based on the outcomes of previous treatments. This approach could lead to more personalized, adaptive treatment strategies that improve patient outcomes.

The application of ML in breast cancer management is rapidly expanding, with numerous studies and real-world implementations demonstrating the potential of these technologies in improving early detection, diagnosis, and treatment planning. Below are some of the key applications of machine learning in the fight against breast cancer. One of the most promising applications of ML in breast cancer care is the enhancement of diagnostic accuracy through automated image analysis (White, 2018). Mammograms, ultrasounds, and magnetic resonance imaging (MRI) are standard imaging modalities used in breast cancer screening, but the interpretation of these images requires a high level of expertise. ML algorithms, particularly deep learning models, have shown remarkable success in analyzing medical images and identifying signs of breast cancer, such as masses or microcalcifications, that might be missed by human radiologists (Mørch *et al*., 2017). Convolutional neural networks (CNNs), a type of deep learning algorithm, have been particularly effective in analyzing mammograms and histopathology slides. Studies have demonstrated that CNNs can achieve diagnostic performance comparable to or even better than radiologists in identifying breast cancer. These algorithms can also assist in screening programs, especially in areas with a shortage of skilled radiologists, by automating the initial interpretation of images and providing a second opinion (Del, 2019). Furthermore, ML can be used to develop risk prediction models for breast cancer. These models take into account factors such as family history, age, hormonal factors, and genetic predispositions to estimate a person's risk of developing breast cancer (Samson, 2016). By identifying individuals at high risk, these models can help prioritize those who would benefit most from early screening and preventive measures. Once breast cancer is detected, accurate diagnosis is crucial for determining the appropriate treatment plan. ML can assist in diagnosing the specific type of breast cancer by analyzing histopathology images or genetic data Kumar, 2019). For example, ML algorithms can identify cancer subtypes based on molecular patterns, which can provide valuable information for treatment decisions. In addition, ML can be used to predict the likelihood of metastasis (spread of cancer to other parts of the body). By analyzing clinical and imaging data, ML models can assess whether a patient's breast cancer is likely to spread, which can help guide treatment decisions. Early detection of metastasis allows for more aggressive treatment options, improving the chances of survival.

Personalized medicine is an approach that tailors treatment to the individual characteristics of each patient. In the case of breast cancer, personalized treatment is based on factors such as the cancer's molecular profile, the patient's genetic makeup, and their overall health. ML can be used to analyze large datasets of patient information to develop personalized treatment plans. For example, ML algorithms can predict how a patient will respond to different chemotherapy drugs, enabling oncologists to select the most effective treatment for each individual. Additionally, ML can help identify biomarkers that predict which patients are likely to benefit from targeted therapies, such as hormone therapy or immunotherapy (Ahmad, 2013). By matching patients with the most effective treatments, ML can improve treatment outcomes and minimize unnecessary side effects. Beyond direct patient care, ML can also optimize healthcare operations, ensuring that resources are used efficiently and effectively. For instance, ML algorithms can be used to predict patient demand in hospitals, helping to allocate resources such as hospital beds, staff, and equipment. In the context of breast cancer care, this could improve access to treatment and reduce waiting times for diagnosis and therapy.

2.3 Implementing ML Technologies for Breast Cancer Management in Sub-Saharan Africa

The implementation of machine learning (ML) technologies for breast cancer management in Sub-Saharan Africa presents a significant opportunity to address the region’s growing cancer burden (Ahmad, 2013). However, achieving effective utilization of these technologies requires a structured approach, integrating the role of data collection and availability, learning from successful case studies globally, and tailoring ML applications for early detection, treatment planning, and personalized medicine to the unique context of Sub-Saharan Africa. While the region faces several challenges in the adoption of ML, such as limited infrastructure and resource constraints, the potential for transformative impact is substantial.

2.3.1 The Role of Data Collection and Availability in the Effective Use of ML Technologies

Data is the backbone of any ML application, as algorithms require large, high-quality datasets to learn patterns and make accurate predictions (Harz, 2014). In healthcare, especially in cancer management, the quality, quantity, and diversity of data are crucial for developing effective ML models. For ML technologies to be successfully implemented in Sub-Saharan Africa, several aspects of data collection and availability must be addressed. Sub-Saharan Africa faces considerable challenges in the collection and management of healthcare data. In many countries, there are no centralized or standardized systems for collecting patient data, making it difficult to gather large, representative datasets that are essential for training ML models. This is further complicated by inconsistent or nonexistent cancer registries and incomplete patient records, particularly in rural areas where access to healthcare facilities is limited. Additionally, the region has a lack of trained personnel to collect and standardize healthcare data, leading to data quality issues (Harz, 2014). Without consistent data collection protocols, it becomes challenging to create reliable ML models that can deliver accurate results. This issue is compounded by privacy concerns and the lack of a legal framework governing data sharing and protection in many Sub-Saharan African countries. For ML technologies to function effectively, it is essential that healthcare data is not only collected but also stored in formats that are compatible with machine learning tools. This requires the digitization of healthcare records and the integration of various types of data, such as medical images (e.g., mammograms), patient demographics, clinical notes, genetic information, and treatment outcomes. In countries like South Africa and Kenya, there have been efforts to digitize medical records, but widespread integration across the entire healthcare system remains a challenge. The availability of large-scale datasets is vital for training accurate and reliable models (Ahmad, 2013). For breast cancer, datasets containing imaging data (such as mammograms or ultrasounds) as well as clinical data (e.g., risk factors, treatment regimens) are particularly important. Furthermore, international collaboration and data-sharing initiatives can help overcome local data scarcity, enabling the development of more generalizable models. To successfully deploy ML in healthcare, especially in the context of breast cancer management, countries in Sub-Saharan Africa must invest in robust data infrastructure. This includes setting up centralized data repositories, establishing data-sharing agreements, and ensuring that healthcare institutions have the necessary technology and resources to maintain accurate, up-to-date records (Harz, 2014). Governments, non-governmental organizations, and international partners can play a role in supporting these infrastructure developments.

2.3.2 Case Studies and Examples from Other Regions or Countries

Several countries outside of Sub-Saharan Africa have successfully implemented ML in healthcare, providing valuable insights and lessons for the region. These case studies highlight how ML technologies can be adapted to improve breast cancer care, even in low-resource settings.

India – AI for Breast Cancer Detection: In India, where access to quality healthcare and radiologists is limited, a number of ML-based systems have been implemented to assist in the early detection of breast cancer. Researchers have developed algorithms that analyze mammograms and histopathology slides to detect malignancies with high accuracy. These systems use deep learning models such as convolutional neural networks (CNNs), which have been trained on large datasets of medical images (Shubbar, 2017). A study published by Indian researchers demonstrated that an AI model for mammogram analysis could achieve diagnostic accuracy comparable to human radiologists. Such tools have been integrated into healthcare systems in urban centers to aid radiologists and serve as a second opinion. These systems have improved the early detection rates of breast cancer and reduced the diagnostic burden on healthcare workers.

Brazil – ML in Cancer Diagnosis and Treatment: In Brazil, ML technologies have been incorporated into public healthcare systems to improve cancer diagnosis and treatment decisions. A major application has been the development of predictive models that help identify patients at high risk of developing breast cancer based on a variety of factors such as family history, lifestyle, and genetic markers (Shubbar, 2017). These tools help prioritize individuals for screening and preventive interventions. Moreover, reinforcement learning algorithms have been used to optimize cancer treatment regimens, enabling clinicians to adjust therapies in real-time based on patient response. These ML models have shown that integrating AI into healthcare systems can enhance diagnosis, optimize treatment planning, and reduce the time to intervention, especially in under-resourced settings. The Brazilian experience demonstrates that effective ML implementation requires not only technological solutions but also strong policy support and a commitment to integrating AI into routine healthcare practices.

United Kingdom – Predictive Models for Early Detection: The United Kingdom has been at the forefront of applying ML in breast cancer screening programs (Mu, 2008). A study conducted by the National Health Service (NHS) used machine learning algorithms to assist in the interpretation of mammograms, and the results were compared to human radiologists. The ML system showed an ability to reduce false positives and false negatives, thereby improving the accuracy and efficiency of breast cancer screening programs (Oliveira *et al*., 2018). The success of such programs has highlighted the potential of ML to improve the early detection of cancer. Moreover, this system was integrated into the NHS's existing infrastructure, which helped to streamline its adoption and ensure its widespread use. The key takeaway from the UK's experience is the importance of combining ML technologies with strong healthcare systems, as well as the need for continuous evaluation to ensure their effectiveness.

2.3.3 Specific ML Applications for Early Detection

One of the most promising applications of ML in breast cancer management is in the field of medical imaging. ML algorithms, especially deep learning models, are being used to analyze mammograms, ultrasounds, and MRIs for signs of breast cancer (Shaikh *et al*., 2021). In Sub-Saharan Africa, where access to skilled radiologists is limited, these automated systems could serve as an essential tool for early cancer detection (Patel *et al*., 2022). Deep learning algorithms, particularly convolutional neural networks (CNNs), are capable of detecting subtle patterns in medical images that may be difficult for human eyes to discern. These models can differentiate between benign and malignant tumors, reducing the risk of missed diagnoses and improving patient outcomes. Implementing such technologies in Sub-Saharan Africa could significantly enhance early detection rates, even in remote or underserved areas. In addition to image analysis, ML can be used to develop risk prediction models that assess an individual's likelihood of developing breast cancer. These models use a variety of data points, including family history, age, genetic information, and lifestyle factors, to estimate a person's risk. For Sub-Saharan Africa, where genetic data may be limited but environmental and lifestyle factors can still be assessed, these models can help prioritize women for regular screening and preventive care (Benagiano *et al*., 2006). By integrating risk prediction into healthcare systems, Sub-Saharan African countries can create more targeted and efficient screening programs, ensuring that those at highest risk are identified early and receive timely intervention.

2.3.4 ML Applications in Treatment Decisions and Personalized Medicine

Personalized medicine, which tailors treatment plans based on the individual characteristics of each patient, can be greatly enhanced through ML. By analyzing genetic data, clinical histories, and patient responses to previous treatments, ML algorithms can predict which therapies are most likely to be effective for a given patient. In breast cancer management, ML models can help determine whether a patient will benefit from chemotherapy, hormone therapy, or targeted therapies, such as HER2 inhibitors (Van der Westhuizen & Van der Merwe, 2011). In Sub-Saharan Africa, where treatment options are often limited and costly, personalized treatment can improve outcomes and reduce unnecessary side effects by focusing on the most effective treatment for each patient. ML can also be integrated into clinical decision support systems to assist healthcare providers in making real-time treatment decisions. These systems can analyze patient data, clinical guidelines, and research literature to suggest optimal treatment regimens. For example, reinforcement learning algorithms can continually adjust recommendations based on the patient's progress, improving the chances of achieving the best possible outcome. ML can be used to optimize cancer treatment regimens by analyzing data from large patient cohorts to determine the most effective dosing schedules, combination therapies, and treatment durations (Cipriani *et al*., 2020). In Sub-Saharan Africa, where access to medication and treatment resources can be limited, optimizing these regimens can reduce waste, improve efficiency, and ensure that patients receive the most appropriate care. The implementation of ML technologies in breast cancer management in Sub-Saharan Africa holds immense promise for improving early detection, diagnosis, and treatment outcomes. However, successful adoption requires addressing challenges related to data collection, infrastructure, and integration into existing healthcare systems. By learning from global case studies, adapting ML applications to the regional context, and investing in the necessary data infrastructure, Sub-Saharan Africa can leverage the power of machine learning to transform breast cancer care (Verma *et al*., 2022). Through targeted efforts, ML can significantly reduce the burden of breast cancer in the region and improve survival rates for countless women.

2.4 Challenges and Barriers to Implementation

While machine learning (ML) technologies have the potential to transform breast cancer management in Sub-Saharan Africa, their implementation is fraught with significant challenges and barriers. These obstacles range from infrastructure limitations to ethical concerns, and addressing them will require a comprehensive and collaborative approach involving government, healthcare providers, international organizations, and technological partners (Stanczyk *et al*., 2013). Below, we explore the main challenges that hinder the widespread adoption and effective use of ML in healthcare in Sub-Saharan Africa, particularly in breast cancer management.

2.4.1 Limited Access to Healthcare Facilities and Resources in Sub-Saharan Africa

One of the most significant barriers to the implementation of ML technologies for breast cancer management in Sub-Saharan Africa is the limited access to healthcare facilities, resources, and services. The healthcare infrastructure in many countries in the region is underdeveloped, especially in rural areas, where the majority of the population resides. This lack of access to medical facilities and specialized care can severely hinder the diagnosis, treatment, and follow-up care of breast cancer patients (Sitruk-Ware *et al*., 2013). In many parts of Sub-Saharan Africa, there is a shortage of essential medical equipment, such as mammography machines, and inadequate healthcare infrastructure for performing diagnostic tests. In rural and remote areas, where there may be limited access to doctors or radiologists, patients often have to travel long distances to reach healthcare centers that can perform even basic diagnostic procedures (Wiegratz & Kuhl, 2004). Without widespread access to diagnostic tools and facilities, the potential of ML technologies to enhance early detection and treatment planning is undermined. Moreover, the scarcity of healthcare professionals—especially those with specialized expertise in oncology—further exacerbates the problem. Radiologists, pathologists, and oncologists are in short supply, with many working in large cities or abroad (Wu *et al*., 2015). The availability of trained professionals is a significant barrier to both adopting ML technologies in routine practice and utilizing them effectively in diagnosis and treatment planning. In this context, while ML can offer solutions to assist healthcare providers in diagnosing and treating breast cancer, the lack of physical healthcare infrastructure can severely limit its effectiveness. For ML technologies to be adopted, healthcare systems must first improve infrastructure to provide the necessary tools and resources for their integration.

2.4.2 Data Quality and the Challenge of Obtaining Diverse Datasets

Machine learning algorithms rely heavily on high-quality, diverse datasets for training, validation, and optimization. One of the key challenges to the successful implementation of ML technologies in Sub-Saharan Africa is the availability and quality of medical data (Shukla *et al*., 2017). In many parts of the region, healthcare data is sparse, inconsistent, and often unreliable, making it difficult to train robust ML models that can deliver accurate and generalizable predictions. In many Sub-Saharan African countries, healthcare data is not consistently collected or stored in standardized formats. This is particularly true for breast cancer, where there is often no centralized cancer registry, and available data is limited to a small number of patients who seek care in urban hospitals. Many women with breast cancer never receive a formal diagnosis or treatment, especially in rural areas, further limiting the amount of data that is available for training machine learning models (Burkman *et al*., 2011). Even when data is available, it often lacks the diversity needed to create accurate models for a heterogeneous population. ML models trained on datasets from populations with different demographics, medical histories, and risk factors may not generalize well to the unique population in Sub-Saharan Africa. For example, certain genetic mutations, risk factors, and tumor characteristics may be more common in African populations, but there is a lack of data to reflect these regional differences (Dragoman, 2014). Without diverse datasets that represent the unique epidemiology and genetic profiles of African populations, ML models may underperform or fail to detect critical health issues accurately. Even if data is available, it may not be standardized. Inconsistent formats, incomplete data, and discrepancies in diagnostic criteria pose challenges to creating machine learning models. Moreover, due to a lack of established frameworks for data collection, many datasets might be unstructured or difficult to work with, making it difficult to extract the necessary features for training algorithms (Riondino *et al*., 2019). Overcoming these challenges requires concerted efforts to improve data collection practices, create national and regional cancer registries, and ensure that healthcare data is accurately and consistently captured. Additionally, it is crucial that datasets are diversified, incorporating data from both rural and urban populations to ensure that machine learning models reflect the realities of Sub-Saharan African healthcare.

2.4.3 Lack of Healthcare Professionals Trained in Machine Learning Technologies

The successful integration of ML into healthcare requires healthcare professionals who are both skilled in medical practices and trained in the fundamentals of machine learning. However, there is a severe shortage of professionals in Sub-Saharan Africa who possess the necessary knowledge and skills in both fields (Seo *et al*., 2015). While medical professionals in the region are well-versed in traditional diagnostic and treatment practices, they often lack exposure to new technologies such as artificial intelligence and machine learning. Training in machine learning is often limited to specific sectors, such as computer science or engineering. For healthcare professionals to effectively use ML technologies in breast cancer management, they need to have a strong understanding of both medical concepts and machine learning algorithms. Currently, educational programs that provide cross-disciplinary training in healthcare and machine learning are rare in Sub-Saharan Africa (Hager *et al*., 2022). Even for those who have received training in machine learning, there is often a lack of practical experience in applying these technologies to real-world healthcare scenarios. Theoretical knowledge may not always translate into effective clinical application, and healthcare workers may struggle to understand how ML algorithms should be integrated into their workflow. This gap in understanding may lead to resistance to adopting ML technologies, particularly in settings where healthcare workers are already under significant pressure (Westbrook & Stearns, 2013). Addressing this challenge requires a concerted effort to develop specialized training programs that bridge the gap between healthcare and technology. Universities, healthcare institutions, and international partners should collaborate to create interdisciplinary training courses that equip healthcare professionals with the skills they need to effectively use ML technologies in their practice.

2.4.4 Ethical Concerns, Privacy, and Data Security in Using ML for Medical Purposes

The use of machine learning in healthcare raises significant ethical concerns, particularly around data privacy, informed consent, and the potential for algorithmic bias (Dalene Skarping, 2020). These issues are especially pertinent in Sub-Saharan Africa, where regulatory frameworks for data privacy and security are often underdeveloped. ML models require access to large volumes of personal health data, including sensitive information such as patient medical histories, genetic profiles, and treatment outcomes. In many Sub-Saharan African countries, there is limited regulation around data privacy, and the security of medical data may not be guaranteed. This raises concerns about potential misuse or unauthorized access to sensitive health information. The use of ML in healthcare must be accompanied by clear informed consent processes to ensure that patients understand how their data will be used. This can be particularly challenging in resource-limited settings where patients may not be fully aware of the implications of data sharing or how their data will be used by ML algorithms (Mathew *et al*., 2021). ML models are only as good as the data they are trained on. If datasets are not diverse or are biased toward certain populations, the resulting algorithms can perpetuate and even exacerbate existing health disparities. For example, an ML model trained on predominantly Western or urban data might perform poorly when applied to rural African populations, where environmental, genetic, and healthcare access factors differ (Thompson *et al*., 2019). This bias can lead to inaccurate diagnoses or suboptimal treatment recommendations for African patients. To address these ethical concerns, it is essential to establish clear guidelines and regulatory frameworks for data privacy, security, and the ethical use of machine learning in healthcare. These frameworks should prioritize patient consent, transparency, and the responsible handling of sensitive data.

2.4.5 Infrastructure Challenges, Such as Internet Connectivity and Access to Technology

Effective implementation of ML technologies requires access to stable internet connectivity, modern computational tools, and the infrastructure to support their deployment. In many parts of Sub-Saharan Africa, these infrastructure challenges remain significant barriers. In many rural areas, internet access is limited, unreliable, or prohibitively expensive (Rajaneesh, 2021). This lack of connectivity hinders the ability to store and access large datasets, run complex ML algorithms in real-time, or integrate cloud-based solutions into healthcare systems. Without internet connectivity, it becomes difficult to leverage the full potential of ML for breast cancer management. Healthcare facilities in Sub-Saharan Africa often lack the necessary computational power to run advanced ML algorithms, particularly those requiring high-performance computing, such as deep learning models for image analysis. Many hospitals and clinics also lack the infrastructure to support the deployment of ML systems, including the necessary hardware and software (Mahboobnia *et al*., 2021). Furthermore, the high costs associated with acquiring and maintaining this technology can be prohibitive for many healthcare systems. Frequent power outages and inconsistent electricity supply are common in many African countries, further hindering the implementation of technology-driven healthcare solutions. In such environments, it is difficult to rely on ML technologies that require stable power sources to function effectively (Santen *et al*., 2010). Addressing these infrastructure challenges will require significant investment in technology, the expansion of internet access, and the development of local solutions that can operate in low-resource environments. Partnerships between governments, international donors, and the private sector will be critical in overcoming these barriers.

The challenges and barriers to implementing ML technologies for breast cancer management in Sub-Saharan Africa are multifaceted, involving issues related to infrastructure, data quality, ethical concerns, and the availability of skilled professionals (Dias *et al*., 2016). While these obstacles are significant, they are not insurmountable. By addressing these challenges with a combination of targeted investment, capacity building, and international collaboration, Sub-Saharan Africa can unlock the potential of ML to revolutionize breast cancer diagnosis, treatment, and outcomes. Overcoming these barriers will be crucial in ensuring that ML technologies are accessible, effective, and ethical in the context of the region's unique healthcare needs.

2.5 Solutions and Recommendations

To overcome the challenges and barriers preventing the effective implementation of machine learning (ML) technologies in breast cancer management in Sub-Saharan Africa, comprehensive solutions must be pursued (Chalfant & Hoyt, 2022). These solutions require collaborative efforts across governments, international organizations, the healthcare sector, and the technology industry. Additionally, there is a need for region-specific models, infrastructure development, and policy reforms to support the widespread integration of ML technologies in healthcare. The following recommendations outline key strategies to harness the potential of ML in breast cancer care, while addressing the unique needs and constraints of Sub-Saharan Africa.

2.5.1 The Need for Partnerships Between Governments, International Organizations, and the Tech Industry

One of the most critical solutions to the challenges faced in implementing ML technologies in Sub-Saharan Africa is fostering strong partnerships between governments, international organizations, the healthcare sector, and the tech industry (Fischer, 2016). Collaboration at multiple levels is essential for the successful deployment and integration of ML into healthcare systems. Governments in Sub-Saharan Africa play a central role in creating the policy environment necessary to support the adoption of ML technologies. They must prioritize digital health and cancer care in national health plans, allocate funding for infrastructure development, and support the creation of healthcare regulations that ensure the safe and ethical use of ML (Brooks *et al*., 2021). Governments can also incentivize the training of healthcare workers in data science and ML, thus building a pool of local talent equipped to implement and manage these technologies. International organizations, such as the World Health Organization (WHO), the African Union (AU), and non-governmental organizations (NGOs), can provide critical support in terms of funding, expertise, and resources. These organizations can help establish frameworks for data sharing, create standards for healthcare data collection, and facilitate the exchange of knowledge between Sub-Saharan Africa and countries that have already successfully integrated ML into their healthcare systems. Furthermore, they can help bridge the technological gap by providing access to necessary tools, such as cloud services and computational infrastructure, in resource-limited settings (Burke, 2010). The technology sector, especially companies specializing in artificial intelligence (AI) and machine learning, can play an important role by partnering with governments and healthcare providers to design and deploy ML solutions tailored to the region's needs. Tech companies can contribute their expertise in algorithm development, data analytics, and systems integration, while also providing the infrastructure needed for ML applications, such as cloud platforms, AI models, and computing resources. Additionally, the tech industry can support the development of region-specific ML tools that are optimized for local healthcare contexts, taking into account the unique demographic, environmental, and healthcare challenges faced by Sub-Saharan Africa (Oskar, 2021). By establishing strategic partnerships between these stakeholders, Sub-Saharan Africa can create an ecosystem conducive to the successful implementation and scaling of ML technologies in healthcare.

2.5.2 The Importance of Improving Healthcare Infrastructure and Training Healthcare Workers

A cornerstone of any successful ML implementation in healthcare is robust infrastructure, both in terms of physical healthcare facilities and technological resources (White, 2015). However, addressing infrastructure alone will not be sufficient—there must also be an emphasis on the education and training of healthcare workers. Governments and international organizations must invest in improving healthcare infrastructure, particularly in rural and underserved areas (Dannhauser & Van den Berg, 2011). This includes expanding access to diagnostic technologies such as mammography machines, ultrasound devices, and biopsy facilities. In addition, improving internet connectivity and ensuring that healthcare facilities have reliable electricity and computing infrastructure is critical for the successful deployment of ML technologies. Telemedicine platforms could also be an essential tool in bridging gaps in access to specialists, enabling remote consultations and diagnostic support in areas where there is a shortage of oncologists and radiologists (Masarwah, 2016). The integration of ML technologies into healthcare requires a workforce that is not only skilled in traditional medical practices but also capable of understanding and applying machine learning algorithms. Training programs for healthcare workers should be designed to equip them with both clinical and technological expertise. For example, doctors and nurses can receive basic training in data science and ML concepts, while radiologists and oncologists can benefit from more specialized training in ML applications for diagnostic imaging, risk prediction, and personalized treatment (Feng *et al*., 2016). A concerted effort to create continuous professional development opportunities, such as online courses, workshops, and partnerships with universities and tech companies, will ensure that healthcare workers in Sub-Saharan Africa are well-prepared to integrate ML into their practices. These training programs can be customized to reflect the region's healthcare needs and the specific challenges of working in low-resource settings. In addition to training healthcare professionals, it is important to engage local communities in the implementation of ML technologies. Public education campaigns can help raise awareness of the benefits of ML in breast cancer detection and treatment, as well as promote early screening and preventive care (Monteiro *et al*., 2013). Engaging community leaders, patient advocacy groups, and local media outlets can help build trust in ML technologies and encourage their acceptance among patients and healthcare workers.

2.5.3 Developing Region-Specific ML Models Using Local Data for Better Prediction and Treatment

One of the most pressing needs in the deployment of ML technologies in Sub-Saharan Africa is the development of region-specific models that can provide accurate predictions and treatment recommendations tailored to the local population. Global ML models may not perform as well in Sub-Saharan Africa due to differences in genetics, risk factors, healthcare access, and environmental factors (De Hert *et al*., 2016). For ML models to be effective in Sub-Saharan Africa, they must be trained on local datasets that capture the unique characteristics of the population. This includes demographic factors (such as age, ethnicity, and family history), geographic factors (such as rural vs. urban settings), and clinical variables (such as common types of breast cancer in the region). Efforts should be made to establish regional cancer registries, collect high-quality medical imaging data, and gather information on risk factors and treatment outcomes (Wong *et al*., 2011). Data collection efforts should involve collaboration between healthcare providers, governments, and international organizations to ensure that data is collected systematically and standardized across different countries. This would help create a comprehensive, representative dataset that could be used to train machine learning algorithms. Ethical considerations related to data privacy, consent, and security must also be addressed when collecting and sharing sensitive health data. Once local data is gathered, ML models should be specifically customized to the African context. For example, breast cancer risk prediction models should incorporate locally relevant risk factors such as lifestyle habits, genetic predispositions, and common co-morbidities (García Damián, 2020). Similarly, algorithms used for diagnostic imaging (e.g., mammogram analysis) should be trained using medical images from African patients to ensure they are capable of accurately detecting breast cancer in the region's population. Customizing algorithms ensures that the models are both effective and equitable in their application.

2.5.4 Policy Recommendations to Support the Integration of ML Technologies in Healthcare

For ML technologies to be successfully integrated into healthcare systems in Sub-Saharan Africa, a strong policy framework is required. This framework should focus on creating a conducive environment for the adoption of ML in healthcare while addressing ethical, regulatory, and operational challenges. Governments should work to establish clear regulations that govern the use of ML technologies in healthcare. These regulations should cover key aspects such as patient privacy, data security, algorithm transparency, and the accountability of ML systems (Hasyim, 2020). This would provide a legal foundation for the use of ML technologies, ensuring that they are used ethically and responsibly. Public and private sector funding is critical to support the development and deployment of ML technologies in healthcare. Governments should allocate resources to promote ML research, support pilot projects, and incentivize the use of AI in clinical settings. Additionally, tax incentives and grants could encourage private companies to invest in developing ML solutions for breast cancer care. Sub-Saharan African countries should develop national strategies for the integration of digital health and ML technologies into their healthcare systems (Quinn, 2020). These strategies should include clear objectives, timelines, and benchmarks for the adoption of ML in healthcare. A regional strategy, aligned with the African Union's health goals, could promote cross-border collaboration and share best practices for ML implementation in breast cancer care. Governments should foster public-private partnerships (PPPs) to bring together the resources and expertise needed to scale ML technologies in healthcare. Through PPPs, governments can leverage the innovation and technological capacity of private companies, while also ensuring that public health needs are prioritized. The effective implementation of machine learning technologies for breast cancer management in Sub-Saharan Africa holds immense potential for improving early detection, treatment planning, and patient outcomes (Kurta, 2013). However, realizing this potential requires a multifaceted approach that addresses infrastructure challenges, promotes local data collection, builds healthcare worker capacity, and establishes strong policy frameworks. By fostering partnerships between governments, international organizations, the tech industry, and healthcare providers, Sub-Saharan Africa can develop tailored ML solutions that are both effective and equitable. Ultimately, by embracing these solutions and recommendations, Sub-Saharan Africa can enhance its healthcare systems and improve the lives of millions of women affected by breast cancer (Passey, 2017).

2.6 Conclusion

There is enormous potential to transform healthcare delivery, increase diagnostic accuracy, customize treatment regimens, and ultimately improve patient outcomes by using machine learning (ML) and algorithmic technologies into breast cancer therapy in Sub-Saharan Africa. Despite the region's particular difficulties with manpower shortages, data accessibility, and healthcare infrastructure, machine learning (ML) offers a game-changing chance to close gaps in the treatment of breast cancer, one of the main causes of cancer-related deaths in Sub-Saharan Africa. Looking ahead, it is evident that the efficient application of these technologies can lead to notable advancements in breast cancer patient survival rates, individualized treatment, and early diagnosis. Algorithmic and machine learning technologies have shown promise in improving the treatment of breast cancer in a number of crucial areas. By leveraging large datasets and advanced algorithms, ML can assist healthcare providers in diagnosing breast cancer more accurately and swiftly, even in settings with limited access to specialized medical professionals. With early detection being crucial to improving survival outcomes, ML-powered image analysis tools, such as those used for mammography, ultrasound, and histopathology images, can detect tumors and abnormalities that might otherwise go unnoticed. Additionally, ML models can predict patient risk factors based on a variety of demographic, clinical, and environmental data, enabling earlier interventions and personalized prevention strategies. In terms of treatment, ML algorithms can support decision-making by recommending personalized treatment plans tailored to an individual's specific tumor characteristics, genetic makeup, and response to previous therapies. This personalized approach can not only optimize the effectiveness of treatments but also reduce unnecessary side effects, thus improving the quality of life for patients. Furthermore, ML-powered tools can assist in monitoring patient progress and predicting outcomes, enabling timely adjustments to treatment regimens. Moreover, the development of predictive models for relapse, prognosis, and survival rates can inform healthcare providers, allowing for better follow-up care, resource allocation, and targeted interventions. With these technologies, healthcare providers in Sub-Saharan Africa could make more informed decisions despite limited resources, ultimately leading to improved survival rates for patients diagnosed with breast cancer.

While the potential benefits of ML technologies for breast cancer management in Sub-Saharan Africa are immense, there are considerable challenges that must be addressed to fully realize these benefits. Limited access to healthcare infrastructure, a shortage of trained professionals, poor data availability, and infrastructure challenges such as unreliable internet connectivity are significant obstacles that hinder the effective deployment of ML solutions. However, overcoming these challenges is not only possible but essential for improving the survival rates of breast cancer patients in the region. Improving healthcare infrastructure, particularly in rural and underserved areas, is a critical first step. Governments and international organizations must prioritize investment in both diagnostic tools and healthcare facilities to ensure that ML technologies can be effectively integrated. Expanding the reach of healthcare services, improving transportation networks to healthcare facilities, and ensuring that patients have access to basic screening services are foundational to the successful application of ML in the region. Additionally, capacity-building efforts to train healthcare professionals in both medical and technological skills are essential. These efforts will equip doctors, radiologists, and oncologists with the tools and knowledge needed to use ML technologies effectively in patient care. Given that Sub-Saharan Africa faces a shortage of skilled healthcare workers, it is vital to build a workforce that is capable of utilizing ML as a complement to traditional healthcare practices, ensuring the effective application of these technologies in real-world settings. Moreover, addressing issues surrounding data quality, collection, and sharing is critical for the development of region-specific ML models. Local datasets that accurately reflect the genetic, environmental, and healthcare disparities in Sub-Saharan Africa must be prioritized in order to train models that can provide the best possible results for the region's population. With better data quality and data-sharing frameworks, ML algorithms can be more accurately tailored to meet the needs of Sub-Saharan African women affected by breast cancer. While these challenges are significant, the region's healthcare systems are not without hope. Through concerted efforts from governments, international organizations, tech companies, and healthcare providers, it is possible to overcome these barriers and begin reaping the rewards of ML integration in breast cancer management. The potential to save lives and reduce the burden of breast cancer on families and communities is a driving force that should compel stakeholders to invest in these transformative technologies.

The future of breast cancer management in Sub-Saharan Africa through ML depends not only on the successful implementation of these technologies but also on continued research, investment, and innovation. To ensure the sustainable and equitable use of ML in healthcare, long-term commitments from both local and international stakeholders are essential. Research into how machine learning can be optimized for local contexts will be crucial for adapting and improving existing models. Since breast cancer diagnosis and treatment can vary greatly depending on a patient's geographical location, socio-economic status, and cultural factors, research should focus on developing region-specific models that incorporate the unique epidemiological, clinical, and genetic profiles of Sub-Saharan African populations. Furthermore, research into the most effective ways to integrate ML into existing healthcare systems—considering the limited resources, infrastructure, and workforce in many countries—will ensure that these technologies can be sustainably implemented and maintained. In addition to research, ongoing **investment** in technology, training, and infrastructure is necessary for the long-term success of ML integration in healthcare. Governments, international development agencies, and private-sector partners must allocate funding to develop and implement ML technologies, ensure that they are tailored to local needs, and build the capacity of healthcare systems to sustain these efforts. Investment in infrastructure, including reliable internet connectivity, access to computing resources, and diagnostic tools, is fundamental to ensuring that ML technologies are accessible and functional in Sub-Saharan Africa. Moreover, equitable access to ML-powered healthcare solutions should be a guiding principle of all investment efforts. ML technologies must not only be accessible to patients in wealthier urban areas but should also be made available in rural, underserved regions where access to healthcare is most limited. To achieve this, innovative delivery models, such as telemedicine and mobile health solutions, can be used to bridge the geographical divide and ensure that patients in remote areas receive the same high-quality care as those in urban centers. In conclusion, the integration of ML and algorithmic technologies in breast cancer management presents a transformative opportunity for Sub-Saharan Africa. By improving diagnostic accuracy, enabling personalized treatments, and enhancing patient outcomes, these technologies can dramatically improve the survival rates of breast cancer patients in the region. However, realizing the full potential of ML in breast cancer care will require addressing significant infrastructure challenges, improving data collection, and investing in healthcare workforce training. With continued research, investment, and collaboration between governments, healthcare providers, international organizations, and the tech industry, Sub-Saharan Africa can build a sustainable, equitable healthcare system that leverages the power of ML to save lives and reduce the burden of breast cancer in the region. The future of breast cancer management in Sub-Saharan Africa is one where technology, innovation, and collaboration work together to create a healthier, more hopeful future for millions of women.

3.References

1. Achilonu OJ, Singh E, Nimako G, Eijkemans RM, Musenge E. Rule-based information extraction from free-text pathology reports reveals trends in South African female breast cancer molecular subtypes and Ki67 expression. BioMed Res Int. 2022;2022(1):6157861.
2. Adeoye J, Akinshipo A, Koohi-Moghadam M, Thomson P, Su YX. Construction of machine learning-based models for cancer outcomes in low and lower-middle income countries: A scoping review. Front Oncol. 2022;12:976168.
3. Ahmad MAB. Mining health data for breast cancer diagnosis using machine learning [dissertation]. Canberra (AU): University of Canberra; 2013.
4. Akuoko DE. Big data for better breast cancer treatment [master's thesis]. Manchester (UK): The University of Manchester; 2020.
5. Alli OI, Dada SA. Pharmacist-led smoking cessation programs: A comprehensive review of effectiveness, implementation models, and future directions. Int J Sci Technol Res Arch. 2022;3(2):297–304. Available from: https://doi.org/10.53771/ijstra.2022.3.2.0129
6. Alli OI, Dada SA. Innovative models for tobacco dependency treatment: A review of advances in integrated care approaches in high-income healthcare systems. IRE J. 2021;5(6):273–282. ISSN: 2456-8880.
7. Ampatzis C, Zervoudis S, Iatrakis G, Mastorakos G. Effect of oral contraceptives on bone mineral density. Acta Endocrinol (Buchar). 2022;18(3):355.
8. Beaber EF, Buist DS, Barlow WE, Malone KE, Reed SD, Li CI. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res. 2014;74(15):4078–89.
9. Benagiano G, Bastianelli C, Farris M. Contraception today. Ann N Y Acad Sci. 2006;1092(1):1–32.
10. Boppart SA, Richards-Kortum R. Point-of-care and point-of-procedure optical imaging technologies for primary care and global health. Sci Transl Med. 2014;6(253):253rv2.
11. Boyd NF, Melnichouk O, Martin LJ, Hislop G, Chiarelli AM, Yaffe MJ, Minkin S. Mammographic density, response to hormones, and breast cancer risk. J Clin

Oncol. 2011;29(22):2985–92.
12. Brooks JD, Nabi H, Andrulis IL, Antoniou AC, Chiquette J, Després P, Simard J. Personalized risk assessment for prevention and early detection of breast cancer: Integration and implementation (PERSPECTIVE I&I). J Pers Med. 2021;11(6):511.
13. Burke MM. Functional polymorphisms in the epidermal growth factor family genes and their relationship to the risk and severity of breast cancer [doctoral dissertation]. Manchester (UK): The University of Manchester; 2010.
14. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: Improving the risk-to-benefit ratio. Contraception. 2011;84(1):19–34.
15. Cancino RS, Su Z, Mesa R, Tomlinson GE, Wang J. The impact of COVID-19 on cancer screening: Challenges and opportunities. JMIR Cancer. 2020;6(2):e21697.
16. Chalfant JS, Hoyt AC. Breast density: Current knowledge, assessment methods, and clinical implications. J Breast Imaging. 2022;4(4):357–70.
17. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):3–12.
18. Chui M, Harryson M, Valley S, Manyika J, Roberts R. Notes from the AI frontier: Applying AI for social good [Internet]. 2018 [cited 2024 Feb 10]. Available from: https://www.mckinsey.com
19. Cipriani S, Todisco T, Scavello I, Di Stasi V, Maseroli E, Vignozzi L. Obesity and hormonal contraception: An overview and a clinician's practical guide. Eat Weight Disord Stud Anorexia Bulimia Obes. 2020;25:1129–40.
20. Crouch BT, Gallagher J, Wang R, Duer J, Hall A, Soo MS, Ramanujam N. Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. Sci Rep. 2019;9(1):3461.
21. Dalene Skarping I. Mammographic density: A marker of treatment outcome in breast cancer? [doctoral dissertation]. Lund (SE): Lund University; 2020.
22. Dannhauser A, Van den Berg VL. Prevalence of the known risk factors in women diagnosed with breast cancer at Queen II Hospital, Maseru [doctoral dissertation]. Bloemfontein (ZA): University of the Free State; 2011.
23. De Hert M, Peuskens J, Sabbe T, Mitchell AJ, Stubbs B, Neven P, Detraux J. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: A critical review. Acta Psychiatr Scand. 2016;133(1):5–22.
24. De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: Pharmacology tailored to women's health. Hum Reprod Update. 2016;22(5):634–46.
25. Del Pup L, Codacci-Pisanelli G, Peccatori F. Breast cancer risk of hormonal contraception: Counselling considering new evidence. Crit Rev Oncol Hematol. 2019;137:123–30.
26. Dias JA, Fredrikson GN, Ericson U, Gullberg B, Hedblad B, Engström G, Wirfält E. Low-grade inflammation, oxidative stress and risk of invasive post-menopausal breast cancer: A nested case-control study within the Malmö diet and cancer study. Breast Cancer Res Treat. 2016;155(1):63–70.
27. Dias JA, Fredrikson GN, Ericson U, Gullberg B, Hedblad B, Engström G, *et al*. Low-grade inflammation, oxidative stress and risk of invasive post-menopausal breast cancer—a nested case-control study from the Malmö Diet and Cancer Cohort. PLOS ONE. 2016;11(7):e0158959.
28. Dragoman MV. The combined oral contraceptive pill—recent developments, risks and benefits. Best Practice & Research Clinical Obstetrics & Gynaecology. 2014;28(6):825-34.
29. Elebro K. Androgen and Estrogen Receptors in Breast Cancer: Impact on Risk, Prognosis and Treatment Prediction [dissertation]. 2017.
30. Elkefi S, Layeb SB. Artificial intelligence and operations research in a middle ground to support decision-making in healthcare systems in Africa. Africa Case Studies in Operations Research: A Closer Look into Applications and Algorithms. 2022;51-69.
31. Feng MX, Hong JX, Wang Q, Fan YY, Yuan CT, Lei XH, *et al*. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast cancer cells and osteoclasts. Scientific Reports. 2016;6(1):19074.
32. Fischer A. Life Events, Perceived Stress and Breast Cancer Risk in the Hereditary Breast and Ovarian Cancer Study of Orange County, CA [dissertation]. UC Irvine; 2016.
33. García Damián A. Disease Biomarkers in Metabolomics. 2020.
34. Grindlay K, Burns B, Grossman D. Prescription requirements and over-the-counter access to oral contraceptives: a global review. Contraception. 2013;88(1):91-6.
35. Gupta A, Anand A, Hasija Y. Recall-based machine learning approach for early detection of cervical cancer. In: 2021 6th International Conference for Convergence in Technology (I2CT). IEEE; 2021. p. 1-5.
36. Hager E, Chen J, Zhao L. Minireview: parabens exposure and breast cancer. International Journal of Environmental Research and Public Health. 2022;19(3):1873.
37. Hampson E. A brief guide to the menstrual cycle and oral contraceptive use for researchers in behavioral endocrinology. Hormones and Behavior. 2020;119:104655.
38. Haney K, Tandon P, Divi R, Ossandon MR, Baker H, Pearlman PC. The role of affordable, point-of-care technologies for cancer care in low-and middle-income countries: a review and commentary. IEEE Journal of Translational Engineering in Health and Medicine. 2017;5:1-14.
39. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology. 2004;230(1):29-41.
40. Harz M. Complexity Reduction in Image-Based Breast Cancer Care [dissertation]. Staats-und Universitätsbibliothek Bremen; 2014.
41. Hasyim NA. MAGEB2 Antibody as Potential Diagnostic and Predictive Tool in the Progression of Oral Cancer [master's thesis]. University of Malaya (Malaysia); 2020.
42. Helland T. Tamoxifen in the Treatment of Luminal Breast Cancer: Implications of Active Metabolites on Gene Expression, Side Effects and Clinical Outcome. 2019.
43. Ikerionwu C, Ugwuishiwu C, Okpala I, James I, Okoronkwo M, Nnadi C, *et al*. Application of machine and deep learning algorithms in optical microscopic

detection of Plasmodium: A malaria diagnostic tool for the future. Photodiagnosis and Photodynamic Therapy. 2022;40:103198.
44. Kanadys W, Barańska A, Malm M, Błaszczuk A, Polz-Dacewicz M, Janiszewska M, *et al*. Use of oral contraceptives as a potential risk factor for breast cancer: a systematic review and meta-analysis of case-control studies up to 2010. International Journal of Environmental Research and Public Health. 2021;18(9):4638.
45. Kennedy CE, Yeh PT, Gonsalves L, Jafri H, Gaffield ME, Kiarie J, *et al*. Should oral contraceptive pills be available without a prescription? A systematic review of over-the-counter and pharmacy access availability. BMJ Global Health. 2019;4(3):e001402.
46. Kimera R, Kaggwa F, Mwavu R, Mugonza R, Tumuhimbise W, Munguci G, *et al*. Mbarara University of Science and Technology (MUST). Leveraging Data Science for Global Health. 2020;329.
47. Kimera R, Kaggwa F, Mwavu R, Mugonza R, Tumuhimbise W, Munguci G, *et al*. An overview of data science innovations, challenges and limitations towards real-world implementations in global health. 2020.
48. Kiyasseh D, Zhu T, Clifton D. The promise of clinical decision support systems targeting low-resource settings. IEEE Reviews in Biomedical Engineering. 2020;15:354-71.
49. Kumar N. Application of Machine Learning for Breast Cancer Diagnosis [dissertation]. MNIT Jaipur; 2019.
50. Kurta ML. Ovarian Cancer Epidemiology: Risk, Diagnosis, and Prognosis [dissertation]. University of Pittsburgh; 2013.
51. Li MX, Sun XM, Cheng WG, Ruan HJ, Liu K, Chen P, *et al*. Using a machine learning approach to identify key prognostic molecules for esophageal squamous cell carcinoma. BMC Cancer. 2021;21:1-11.
52. Liu ZYC, Chamberlin AJ, Tallam K, Jones IJ, Lamore LL, Bauer J, *et al*. Deep learning segmentation of satellite imagery identifies aquatic vegetation associated with snail intermediate hosts of schistosomiasis in Senegal, Africa. Remote Sensing. 2022;14(6):1345.
53. Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, *et al*. PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy. 2021;140:111758.
54. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, *et al*. Oral contraceptive formulation and risk of breast cancer. Contraception. 2012;85(4):342-50.
55. Masarwah A. Mammographic breast density, tumour characteristics and the expression of hyaluronan as prognostic surrogate markers for breast cancer [dissertation]. Itä-Suomen yliopisto; 2016.
56. Mathew A, Doorenbos AZ, Li H, Jang MK, Park CG, Bronas UG. Allostatic load in cancer: a systematic review and mini meta-analysis. Biol Res Nurs. 2021;23(3):341-61.
57. Monteiro AC, Leal AC, Gonçalves-Silva T, Mercadante ACT, Kestelman F, Chaves SB, *et al*. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS One. 2013;8(7):e68171.
58. Moore JX, Han Y, Appleton C, Colditz G, Toriola AT. Determinants of mammographic breast density by race among a large screening population. JNCI Cancer Spectr. 2020;4(2):pkaa010.
59. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228-39.
60. Moyo D. Breast and cervical cancer prediction using supervised machine learning algorithms. 2022.
61. Mu T. Design of machine learning algorithms with applications to breast cancer detection [dissertation]. University of Liverpool; 2008.
62. Mulukuntla S, Gaddam M. Overcoming barriers to equity in healthcare access: innovative solutions through technology. EPH-Int J Med Health Sci. 2017;3(1):51-60.
63. National Academies of Sciences, Engineering, and Medicine. Optimizing the patient journey by leveraging advances in health care. In: Crossing the Global Quality Chasm: Improving Health Care Worldwide. National Academies Press (US); 2018.
64. Neeman E, Lyon L, Sun H, Conell C, Reed M, Kumar D, *et al*. Future of teleoncology: trends and disparities in telehealth and secure message utilization in the COVID-19 era. JCO Clin Cancer Inform. 2022;6:e2100160.
65. Ngwa W, Olver I, Schmeler KM. The use of health-related technology to reduce the gap between developed and undeveloped regions around the globe. Am Soc Clin Oncol Educ Book. 2020;40:227-36.
66. Oliveira B, Jones E, Glavin M, O'Halloran M. Towards improved breast cancer diagnosis using microwave technology and machine learning [dissertation]. Ph.D. thesis, NUI Galway; 2018.
67. Oskar S. Exposure to phthalates during critical windows of susceptibility and breast tissue composition: implications for breast cancer risk. Columbia University; 2021.
68. Pai V, Baker H, Lash TB. The National Institutes of Health Affordable Cancer Technologies Program: improving access to resource-appropriate technologies for cancer detection, diagnosis, monitoring, and treatment in low- and middle-income countries. 2016.
69. Pan L, Feng Z, Peng S. A review of machine learning approaches, challenges and prospects for computational tumor pathology. arXiv preprint arXiv:2206.01728. 2022.
70. Pareek PK, Surendhar SP, Prasad R, Ramkumar G, Dixit E, Subbiah R, *et al*. [Retracted] Predicting the spread of vessels in initial-stage cervical cancer through radiomics strategy based on deep learning approach. Adv Mater Sci Eng. 2022;2022(1):1008652.
71. Passey A. Epigenetic biomarkers for clinical outcomes and mechanisms driving emergence of drug resistance in ovarian cancer [dissertation]. Imperial College London; 2017.
72. Patel MI, Ferguson JM, Castro E, Pereira-Estremera CD, Armaiz-Peña GN, Duron Y, *et al*. Racial and ethnic disparities in cancer care during the COVID-19 pandemic. JAMA Netw Open. 2022;5(7):e2222009.
73. Quinn J. Evaluation of the role of autophagy in ovarian cancer chemoresistance. 2020.
74. Rajaneesh N. Risk factors in breast cancer: work on preventing recurrence. Notion Press; 2021.
75. Ramanujam N, Crouch B. Democratizing cancer diagnostics and therapeutics through precision medicine. Technol Innov. 2019;20(4):399-413.

76. Ramón y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, *et al*. Mammographic density and breast cancer in women from high-risk families. Breast Cancer Res. 2015;17:1-11.
77. Renner RM, Jensen JT. Progestin-only oral contraceptive pills. Contraception. 2011;40-56.
78. Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in cancer patients: candidate biomarkers and risk assessment models. Cancers. 2019;11(1):95.
79. Saleh M, Naik G, Mwirigi A, Shaikh AJ, Sayani S, Ghesani M, *et al*. Bridging the gap in training and clinical practice in Sub-Saharan Africa. Curr Breast Cancer Rep. 2019;11:158-69.
80. Samson ME. Progesterone-only oral contraceptive pill, breast cancer, heart disease, and stroke. 2016.
81. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, *et al*. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7_supplement_1):s1-66.
82. Santosh KC, Gaur L. Artificial intelligence and machine learning in public healthcare: opportunities and societal impact. Springer Nature; 2022.
83. Seo BR, Bhardwaj P, Choi S, Gonzalez J, Andresen Eguiluz RC, Wang K, *et al*. Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Sci Transl Med. 2015;7(301):301ra130.
84. Shah D, Patil M, National PCOS Working Group. Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India. J Hum Reprod Sci 2018;11(2):96-118.
85. Shaikh K, Krishnan S, Thanki RM. Artificial intelligence in breast cancer early detection and diagnosis. Cham: Springer; 2021. p. 209-49.
86. Shubbar S. Ultrasound medical imaging systems using telemedicine and blockchain for remote monitoring of responses to neoadjuvant chemotherapy in women’s breast cancer: concept and implementation [Master's thesis]. Kent State Univ; 2017.
87. Shukla AK, Jamwal R, Bala K. Adverse effect of combined oral contraceptive pills. Asian J Pharm Clin Res 2017;10:17-21.
88. Shukla AK, Jamwal R, Bala K. Adverse effect of combined oral contraceptive pills. Asian J Pharm Clin Res 2017;10:17-21.
89. Sitruk-Ware R, Nath A, Mishell DR Jr. Contraception technology: past, present and future. Contraception 2013;87(3):319-30.
90. Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics, and risk assessment. Contraception 2013;87(6):706-27.
91. Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L. Aromatase inhibitors—induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci 2020;21(16):5625.
92. Tesic V, Kolaric B, Znaor A, Kuna SK, Brkljacic B. Mammographic density and estimation of breast cancer risk in intermediate risk population. Breast J 2013;19(1):71-8.
93. Thomford NE, Bope CD, Agamah FE, Dzobo K, Owusu Ateko R, Chimusa E, *et al*. Implementing artificial intelligence and digital health in resource-limited settings? Top 10 lessons we learned in congenital heart defects and cardiology. Omics 2020;24(5):264-77.
94. Thompson PA, Preece C, Stopeck AT. Breast cancer prevention. In: Fundamentals of cancer prevention. Springer; 2019. p. 543-606.
95. Upadhya KK, Santelli JS, Raine-Bennett TR, Kottke MJ, Grossman D. Over-the-counter access to oral contraceptives for adolescents. J Adolesc Health 2017;60(6):634-40.
96. Van der Westhuizen E, Van der Merwe E. The safety and efficacy of low-dose oral contraceptives: CPD article. S Afr Fam Pract 2011;53(5):403-11.
97. Verma N, Cwiak C, Kaunitz AM. Hormonal contraception: systemic estrogen and progestin preparations. Clin Obstet Gynecol 2021;64(4):721-38.
98. Waljee AK, Weinheimer-Haus EM, Abubakar A, Ngugi AK, Siwo GH, Kwakye G, *et al*. Artificial intelligence and machine learning for early detection and diagnosis of colorectal cancer in sub-Saharan Africa. Gut 2022;71(7):1259-65.
99. Westbrook K, Stearns V. Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther 2013;139(1):1-11.
100. White A. Multiple sources of PAH exposure, DNA methylation and breast cancer. [Unpublished thesis]. 2015.
101. White ND. Hormonal contraception and breast cancer risk. Am J Lifestyle Med 2018;12(3):224-6.
102. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004;64:2447-62.
103. Wong CS, Lim GH, Gao F, Jakes RW, Offman J, Chia KS, *et al*. Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer 2011;104(5):871-4.
104. Wu L, Janagam DR, Mandrell TD, Johnson JR, Lowe TL. Long-acting injectable hormonal dosage forms for contraception. Pharm Res 2015;32:2180-91.
105. Yaghjyan L, Mahoney MC, Succop P, Wones R, Buckholz J, Pinney S. Relationship between breast cancer risk factors and mammographic breast density in the Fernald Community Cohort. Br J Cancer 2012;106(5):996-1003.
106. Yaghjyan L, Smotherman C, Heine J, Colditz GA, Rosner B, Tamimi RM. Associations of oral contraceptives with mammographic breast density in premenopausal women. Cancer Epidemiol Biomarkers Prev 2022;31(2):436-42.
107. Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther 2013;139(3):392-404.